# 2004 australia dl 2/2024

# Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) $\alpha$ and $\delta$ and PPAR coactivator $1\alpha$ in human skeletal muscle, but not lipid regulatory genes

## M J Watt, R J Southgate, A G Holmes and M A Febbraio

Skeletal Muscle Research Laboratory, School of Medical Sciences, Royal Melbourne Institute of Technology, PO Box 27, Bundoora 3083, Victoria, Australia

(Requests for offprints should be addressed to M J Watt; Email: matthew.watt@rmit.edu.au)

# Abstract

Fatty acids are an important ligand for peroxisome proliferator-activated receptor (PPAR) activation and transcriptional regulation of metabolic genes. To examine whether reduced plasma free fatty acid (FFA) availability affects the mRNA content of proteins involved in fuel metabolism in vivo, the skeletal muscle mRNA content of various transcription factors, transcriptional coactivators and genes encoding for lipid regulatory proteins were examined before and after 3 h of cycle exercise with (NA) and without (CON) pre-exercise ingestion of nicotinic acid (NA). NA resulted in a marked (3- to 6-fold) increase (P<0.05) in PPAR $\alpha$ , PPAR $\delta$  and PPAR coactivator 1 $\alpha$  (PGC1 $\alpha$ ) mRNA, but was without effect on nuclear respiratory factor-1 and Forkhead transcription factor, fatty acid transcolase/CD36, carnitine palmitoyl transferase 1, hormone sensitive lipase (HSL) and pyruvate dehydrogenase kinase 4. Exercise in CON was associated with increased (P < 0.05) PPAR $\alpha$ , PPAR $\delta$  and PGC1 $\alpha$  mRNA, which was similar in magnitude to levels observed with NA at rest. Exercise was generally without effect on the mRNA content of lipid regulatory proteins in CON and did not affect the mRNA content of the measured subset of transcription factors, transcriptional co-activators and lipid regulatory proteins during NA. To determine the possible mechanisms by which NA might affect PGC1a expression, we measured p38 MAP kinase (MAPK) and plasma epinephrine. Phosphorylation of p38 MAPK was increased (P < 0.05) by NA treatment at rest, and this correlated ( $r^2=0.84$ , P<0.01) with increased PGC1a. Despite this close relationship, increasing p38 MAPK in human primary myotubes was without effect on PGC1a mRNA content. Plasma epinephrine was elevated (P < 0.05) by NA at rest (CON:  $0.27 \pm 0.06$ , NA:  $0.72 \pm 0.11$  nM) and throughout exercise. Incubating human primary myotubes with epinephrine increased PGC1a independently of changes in p38 MAPK phosphorylation. Hence, despite the fact that NA ingestion decreased FFA availability, it promoted the induction of PPAR $\alpha/\delta$  and PGC1 $\alpha$  gene expression to a similar degree as prolonged exercise. We suggest that the increase in PGC1a may be due to the elevated plasma epinephrine levels. Despite these changes in transcription factors/coactivators, the mRNA content of lipid regulatory proteins was generally unaffected by plasma FFA availability.

Journal of Molecular Endocrinology (2004) 33, 533-544

# Introduction

Skeletal muscle is a major site of fatty acid uptake and oxidation at rest and during contraction (for review see van der Vusse & Reneman 1996) and aberrant control of fatty acid metabolism is related to obesity and type 2 diabetes (Kelley *et al.* 2002). Chronic exercise improves the capacity to utilize fatty acids by a co-ordinated upregulation of proteins involved in the sarcolemmal uptake (fatty acid translocase; FAT/CD36), mitochondrial transport (carnitine palmitoyl transferase 1; CPT1) and  $\beta$ -oxidation ( $\beta$ -hydroxyacyl-coenzyme-A) of fatty acids (Spina *et al.* 1996, Berthon *et al.* 1998, Bonen *et al.* 1999). The upregulation of these proteins is rapid and due, at least partially, to increased gene expression (Hood 2001). In this regard, increased transcription and expression of several metabolic

Journal of Molecular Endocrinology (2004) 33, 533–544

0952–5041/04/033–533 © 2004 Society for Endocrinology Printed in Great Britain

DOI: 10.1677/jme.1.01499 Online version via http://www.endocrinology-journals.org regulatory genes have been demonstrated immediately after a single prolonged exercise bout (Cortright *et al.* 1999, Pilegaard *et al.* 2000, 2002).

proliferator-activated Peroxisome receptors (PPARs) are a family of nuclear hormone receptors that mediate adaptive metabolic responses by ligand-dependent transcriptional activation of target genes (Kliewer *et al.* 2001). PPAR $\alpha$  and  $\delta$  are considered the most important subtypes in skeletal muscle by virtue of their abundant expression (Braissant et al. 1996). PPAR $\alpha$  mediates transcriptional control of nuclear genes encoding for proteins involved in fuel oxidation, including CPT1, pyruvate dehydrogenase kinase 4 (PDK4) and uncoupling protein 3 (UCP3). Consistent with a central role in fatty acid oxidation, PPARa null mice exhibit decreased expression of lipid regulatory genes, decreased β-oxidation and greater lipid accumulation in hepatic and cardiac tissue (Djouadi et al. 1998). Although much less is known regarding PPAR $\delta$ , recent evidence has demonstrated increased expression of genes involved in lipid catabolism in skeletal muscle cells following acute PPAR $\delta$  activation (Dressel et al. 2003, Wang et al. 2003). The PPARs are activated by naturally occurring fatty acids and fatty acid metabolites, indicating that they act as fatty acid sensors. Since fatty acids and lipid metabolites (e.g. fatty acyl CoA) are ligands of the PPARs and their availability is increased during prolonged exercise (Watt et al. 2003), the marked increase in fatty acid availability during prolonged exercise may provide a stimulus for increased PPAR $\alpha/\delta$  activity and subsequent induction of numerous lipid regulatory genes.

Emerging evidence demonstrates the importance of coactivator molecules in the transcriptional activation of nuclear receptor target genes. Fatty acid induction of gene expression through PPARa and  $\delta$  is enhanced by the PPAR coactivator  $1\alpha$ (PGC1 $\alpha$ ), which is expressed in oxidative tissues such as skeletal and cardiac muscle (Dressel et al. 2003, for review see Puigserver & Spiegelman 2003). Overexpression of PGC1 $\alpha$  and PPAR $\alpha$  in 3T3-L1 adipocytes resulted in the induction of PPAR $\alpha$  target genes and concomitant increases in palmitate oxidation (Vega et al. 2000). Of note, PGC1 $\alpha$  expression is induced during metabolic stresses such as cold exposure (Puigserver et al. 1998), severe caloric restriction (Larrouy et al. 1999) and prolonged exercise (Terada et al. 2002, Pilegaard et al. 2003). In these situations, plasma free fatty acid (FFA) availability is increased dramatically, which provides a clue to a potential mechanism through which  $PGC1\alpha$  gene expression is enhanced.

In the present study, we chose to examine the effect of the anti-lipolytic drug nicotinic acid (NA) on the expression of the nuclear transcription factors, PPAR $\alpha$  and  $\delta$ , the transcriptional coactivator, PGC1 $\alpha$  and various PPAR target genes encoding for proteins involved in lipid metabolism. We hypothesized that decreased plasma FFA availability would suppress the exercise-induced increase in the lipid regulatory genes, PGC1 $\alpha$ , PPAR $\alpha$  and PPAR $\delta$ .

# Materials and methods

#### **Experimental subjects**

The experimental protocol was approved by the Royal Melbourne Institute of Technology human research ethics committee, and written informed consent was obtained prior to testing. All testing was in accordance with the Declaration of Helsinki. Subjects were recreationally active males  $(24 \pm 3 \text{ years}; 80 \pm 3 \text{ kg})$  who participated in two to four aerobic exercise bouts per week.

#### Pre-experimental protocol

Subjects performed an incremental exercise bout to volitional exhaustion to determine peak pulmonary oxygen uptake (VO<sub>2</sub> peak) which averaged  $4.33 \pm 0.31$  litres/min. Expired contents of oxygen and carbon dioxide and ventilation data were collected and analysed on-line (Quark b<sup>2</sup>; COSMED, Rome, Italy). At least 2 days later, subjects completed a practice trial, the purpose of which was to familiarize the subjects with the effects of NA and confirm their ability to perform the exercise bout. Subjects ingested 10 mg/kg NA (Aspen Pharmacare, St Leonards, NSW, Australia) and rested for 60 min, after which they cycled for 120 min at 60% VO<sub>2</sub> peak. Further NA doses (5 mg/kg) were ingested at 30-min intervals at rest (-30 and 0 min) and throughout exercise. For the day preceding each trial, subjects were provided with a food parcel (14 MJ, 80% carbohydrate) and were required to abstain from exercise, caffeine and alcohol. All trials were performed at an ambient temperature of 19–21 °C.

#### **Experimental protocol**

Subjects performed 180 min of cycle exercise at 60% VO<sub>2</sub> peak on two occasions; either with (NA) or without (CON) NA ingestion before and during exercise. The trials were randomly assigned and counter-balanced. Subjects visited the laboratory at 0800 h after an overnight fast. A Teflon catheter was inserted into a forearm vein and was kept patent by saline infusion. A resting blood sample was obtained and the vastus lateralis was prepared for needle biopsy. Three incisions were made through the skin and fascia under local anaesthesia (lidocaine, no epinephrine). During NA, subjects followed the NA ingestion regime as described above. A placebo was not administered in CON subjects because subjects can easily determine the effects of NA ingestion, which include peripheral vasodilation, itchiness and in some instances mild nausea. One blood and one muscle sample were obtained immediately prior to exercise and at 90 and 180 min during exercise. The exercise biopsy samples were obtained while the subjects remained on the cycle ergometer and were rapidly frozen in liquid nitrogen for later analysis. An extra biopsy was not obtained prior to NA ingestion to minimize subject stress, which may have confounded the gene expression measurements. Subjects were not permitted to eat during the trial but were provided with water (1 litre/h) to ensure euhydration.

#### **Blood analysis**

Whole blood was mixed in a sodium-heparin collection tube and the plasma was obtained after centrifugation at 5000 g for 2 min. Plasma samples were frozen at -80 °C for later analysis of FFA by an enzymatic colorimetric method (NEFA C; Wako Chemicals, Richmond, VA, USA), insulin (Coat-a-Count; DPC, Los Angeles, CA, USA) and epinephrine (LDN, Nordhorn, Germany) by radioimmunoassay.

#### **Muscle analysis**

Muscle tissue was homogenized and extracted for total RNA using the acid guanidium thiocyanate-phenol-chloroform extraction method (Chomcyznski & Sacchi 1987) and modified according to methods described elsewhere (Febbraio & Koukoulas 2000). RNA samples were reverse transcribed using a thermal cycler (Perkin Elmer GeneAmp PCR 2400 thermal cycler; Perkin Elmer, Rowville, Victoria, Australia) with Taqman Reverse transcription reagents (Applied Biosystems, Foster City, CA, USA) in 40  $\mu$ l reaction mixtures containing 1× Taqman RT buffer, 5.5 mM MgCl<sub>2</sub>, 500  $\mu$ M 2'-deoxynucleoside 5'-triphosphate, 2.5  $\mu$ M random hexamers, 0.4U/ $\mu$ l RNase inhibitor and 1.25 U/ $\mu$ l multiscribe reverse transcriptase. Control (reverse transcriptase negative) samples were also made and included in all future PCR analyses to check for genomic DNA contamination.

#### **Real-time PCR analysis**

Real-time PCR was employed to quantify the genes of interest. All reactions were performed according to the multiplex comparative critical threshold ( $C_T$ ) method. This method allows for the detection of the reference gene (ribosomal 18S) and the gene of interest in the same well or tube. Preliminary experiments were first performed to determine the efficiency of amplification of 18S vs the gene of interest.

PCR reactions were performed in 96-well plates on a BioRad i-CYCLER iQ real-time PCR detection system in 25 µl reaction volumes consisting of: BioRad iQ Supermix PCR mix  $(2 \times ;$ BioRad, Applied Biosystems, Scoresby, Victoria, Australia), Applied Biosystems pre-developed assay reagent for 18S (Applied Biosystems), the forward and reverse primers and probes of the genes of interest (see Table 1 for sequences) and sterile  $H_2O$ . A  $\Delta C_T$  value was obtained by subtracting 188  $C_T$  values from the  $C_T$  value of the gene of interest. For each gene, the  $\Delta C_T$  value for CON 0 was then subtracted from the  $\Delta C_T$  values of the other time-points for each subject to derive a  $\Delta\text{-}\Delta\mathrm{C}_\mathrm{T}$  value. The expression was then evaluated by  $2-\Delta^{-\Delta C}_{T}$  with all CON 0 values for each subject being 1.

#### Protein analysis

Muscle was homogenized (Polytron; Brinkman Instruments, New York, NY, USA) in ice-cold buffer containing 50 mM HEPES, 150 mM NaCl, 10 mM NaF, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 5 mM EDTA, 0.5% Triton X-100, 10% glycerol (v/v), 2  $\mu$ g/ml leupeptin, 100  $\mu$ g/ml phenylmethylsulfonyl fluoride

Journal of Molecular Endocrinology (2004) 33, 533–544

Table 1 Primer and probe sequences for real-time PCR

	Forward primer	Reverse primer	TaqMan probe
Gene			
CPT1	5'-CTGCAGTGGGACATTCCAAA-3'	5'-CAACGCCTTGGCCACCT-3'	5'-ACTCTCGATGACCGCCTGGCACTG-3'
FAT/36	5'-AGTCACTGCGACTGATTAATGGT-3'	5'-CTGCAATACCTGGCTTTTCTCA-3'	5'-ACAGATGCAGCCTCATTTCCACCTTTTG-3'
FKHR	5'-CGTGCCCTACTTCAAGCATAAGG-3'	5'-CGACTATGCAGTGACAGGTTGTG-3'	5'-TCTGCCGGCTGGAAGAACTCCATC-3'
HSL	5'-ACGCTGCATAAGGGATGCTT-3'	5'-CCTGTCTCGTTGCGTTTGTAGT-3'	5'-AGTTCACGCCTGCCATCCGGC-3'
NRF-1	5'-GGCACTGTCTCACTTATCCAGGTT-3'	5'-CAGCCACGGCAGAATAATTCA-3'	5'-ACCACGGTCACCGTTGCCCAA-3'
PGC1α	5'-CAAGCCAAACCAACAACTTTATCTCT-3'	5'-CACACTTAAGGTGCGTTCAATAGTC-3'	5'-AGTCACCAAATGACCCCCAAGGGTTCC-3'
$PPAR\alpha$	5'-AGCTTTGGCTTTACGGAATACCA-3'	5'-CCACAGGATAAGTCACCGAGGA-3'	5'-TCACGGACACGCTTTCACCAGCTTC-3'
<b>PPAR</b> 8	5'-CACTGAGTTCGCCAAGAGCAT-3'	5'-CACGCCATACTTGAGAAGGGTAA-3'	5'-TCAGCAGCCTCTTCCTCAACGACCA-3'
PDK4	5'-TCCACTGCACCAACGCCT-3'	5'-TGGCAAGCCGTAACCAAAA-3'	5'-ATAATTCCCGGAATGCTCCTTTGGCTG-3'
UCP3	5'-TGACTCCGTCAAGCAGGTGTAC-3'	5'-CAAAATCCGGGTAGTGAGGCT-3'	5'-CCCCCAAAGGCGCGGGACAAC-3'
CPT1, ca	rnitine palmitoly transferase 1; FAT/CD36, fatty acid t	ranslocase; FKHR, forkhead transcription factor; HS	L, hormone sensitive lipase; NRF-1, nuclear respiratory

CPT1, carnitine palmitoly transferase 1; FAT/CD36, fatty acid translocase; FKHH, Torkneau transcription factor, included with the construction of PDK4, pyruvate factor-1; PGC1α, PPAR coactivated receptor δ; PDK4, pyruvate dehydrogenase kinase 4; UCP3, uncoupling protein 3.

and 2 µg/ml aprotinin. Homogenates were centrifuged and the supernatant was removed and rapidly frozen in liquid nitrogen. Protein concentration of the muscle lysates was subsequently determined (Pierce, Rockford, IL, USA). Muscle lysates were solubilized in Laemmli sample buffer and boiled for 5 min, resolved by SDS-PAGE on 10% polyacrylamide gels, transferred to a nitrocellulose membrane, blocked with 5% bovine serum albumin and immunoblotted with the antiphospho-p38 MAP kinase (MAPK), anti-phosphoextracellular regulated kinase (ERK), anti-phosphoc-Jan NH<sub>2</sub>-terminal kinase (JNK) (1:1000; Cell Signaling, Beverley, MA, USA) or anti-PGC1 antibody (Chemicon International, Boronia. Victoria, Australia). After incubation with horseradish peroxidase-conjugated secondary antibody (1:2000; Amersham Biosciences, Castle Hill, NSW, Australia), the immunoreactive proteins were detected with enhanced chemiluminescence (Perkin Elmer) and quantified by densitometry.

#### Primary cell culture

Muscle tissue from the vastus lateralis was obtained via percutaneous needle biopsy and immediately transferred to ice-cold Ham's F-10 media (Gibco, Mt Waverley, Victoria, Australia). The tissue was washed three times in ice-cold Ham's-F10 media to remove any traces of blood, and placed over ice in a sterile Petri dish. The tissue was covered with  $\sim 3 \text{ ml} \ 0.05\%$  Trypsin/EDTA and minced. The homogenate was collected, diluted in 15 ml 0.05% Trypsin/EDTA, agitated for 20 min and the supernatant was collected and stored on ice. This procedure was repeated three times and the supernatant was filtered and then spun for 7 min at 1600 g at room temperature. The cell pellet was re-suspended in growth media ( $\alpha$ -minimum essential medium with 10% fetal calf serum, 0.5%antibiotics and 0.5% amphotericin B) and placed in an uncoated 75 cm flask and incubated for 30 min at 37 °C (95%  $O_2/5\%$  CO<sub>2</sub>) to allow attachment of fibroblasts. The supernatant was collected and placed in another flask pre-coated with extracellular matrix (ECM) and incubated as above for 24 h. Satellite cells appeared after  $\sim 7$ days and were allowed to reach 60-70% confluence, at which point they were sub-cultured into separate dishes. When the myoblasts reached 70% confluence, the growth medium was replaced with differentiation medium (2% horse serum (HS), 0.5% antibiotics and 0.5% antifungal). Myoblasts were maintained in differentiation media until fully fused myotube cultures were obtained.

Experiments were conducted in overnight serum-starved cells. Myotubes (n=12 plates foreach condition) were incubated for 6 h at 37 °C with vehicle (phosphate-buffered saline), 10 µM NA, 500 nM A23187 (calcium ionophore) and 1 µM epinephrine alone or in combination with the specific p38 MAPK inhibitor, SB203580 (10 µM). In one experiment, cells (n=6) were rapidly lysed with the ice-cold buffer used for protein homogenization (see above) and rapidly frozen in liquid nitrogen for later analysis of p38 MAPK phosphorylation. In a second experiment, cells (n=6) were homogenized and extracted for total RNA as described above. RT-PCR was employed to assess PGC1 $\alpha$  mRNA content.

#### Statistical analysis

All values are expressed as means  $\pm$  S.E.M. (n=7). Statistical analysis was performed by two-way ANOVA with repeated measures followed by a Student–Newman–Kuels post hoc analysis to determine specific differences where appropriate. Correlations were examined using a Pearson correlation analysis. SigmaStat version 2.03 (SPSS Incorporated, Chicago, IL, USA) was used to compute these statistics. Statistical significance was set at P < 0.05.

### Results

#### Physiological variables

NA ingestion suppressed (P < 0.05) plasma FFA levels at rest ( $0.41 \pm 0.04$  to  $0.10 \pm 0.01$  mM) and throughout exercise whereas plasma FFA was increased (P < 0.05) from rest at the conclusion of exercise in CON (Table 2). Plasma epinephrine concentration was greater (P < 0.05) before and after exercise in NA compared with CON (Table 2). Plasma insulin concentration decreased (P < 0.05) from rest by the cessation of exercise in both trials and there were no differences between trials (Table 2). **Table 2** Plasma FFA, epinephrine and insulin responses before and after 3 h of exercise with (NA) or without (CON) prior NA ingestion. Values (means  $\pm$  s.E.M.) are expressed as fold change from CON at 0 min (*n*=7)

	Trial	Pre	Post
FFA (mM)	CON	0.32±0.03	1.42±0.07
	NA	0.10±0.01	0.10±0.01
Epinephrine (mM)	CON	0.27±0.06	1.70±0.35
	NA	0.72±0.11*	3.09±0.70*
Insulin (pM)	CON	51.9±4.8	6.9±1.5
	NA	54.7±4.3	6.6±1.7

\*P < 0.05 compared with corresponding time-point for CON.

#### Skeletal muscle mRNA content

#### Transcription factors

PPAR $\alpha$  (3.8-fold) and PPAR $\delta$  (3-fold) were elevated (P < 0.05) at rest in NA compared with CON (Fig. 1). PPAR $\alpha$  and PPAR $\delta$  mRNA were increased (P < 0.05) from rest after exercise in CON, but no such changes were observed in NA. There were no differences between trials after exercise. NRF-1 is a key transcriptional activator of nuclear genes that is transcriptionally activated by PGC1 $\alpha$ and coactivates with PGC1 $\alpha$  to induce mitochondrial biogenesis (Baar et al. 2003). Muscle content of NRF-1 was unaffected by NA ingestion at rest and exercise in both trials (Fig. 2). Although it is well known that the phosphorylation of the FKHR protein is via Akt phosphorylation (Brunet et al. 1999), relatively less is known with respect to the transcriptional regulation of FKHR. Skeletal muscle FKHR mRNA content was not affected by NA ingestion or exercise in NA. FKHR mRNA tended to increase (2-fold, P=0.08) following exercise in CON.

#### Transcriptional coactivators

PGC1 $\alpha$  was markedly (~6 fold) increased (P<0.05) at rest in NA compared with CON (Fig. 3A). After exercise, muscle PGC1 $\alpha$  mRNA content was increased (P<0.05) in CON, whereas no such change was observed in NA. There was no difference in PGC1 $\alpha$  mRNA content after exercise.

#### Lipid regulatory genes

FAT/CD36, HSL, CPT1 and PDK4 mRNA content were not different between trials at rest,



Exercise

**Figure 1** Real-time RT-PCR analysis of (A) PPAR $\alpha$  and (B) PPAR $\delta$  mRNA measured before and after 3 h of moderate exercise with (NA) or without (CON) prior NA administration. Values represent the means±s.E.M. (*n*=7). \**P*<0.05, different from corresponding value for CON; †*P*<0.05, different from 0 min of the same trial.

whereas UCP3 was 3-fold greater (P<0.05) in NA compared with CON (Table 3). Exercise was without effect on CPT1 and HSL mRNA content in both trials, whereas PDK4 was increased (P<0.05, main effect) after exercise (Table 2). Exercise induced a small ( $\sim 2.5$  fold) increase (P<0.05) in FAT/CD36 during NA only. In contrast, UCP3 mRNA was increased (P<0.05) from rest values after exercise in CON, whereas it was decreased post-exercise in NA. There were no differences between trials for UCP3 after exercise.

www.endocrinology-journals.org





**Figure 2** Real-time RT-PCR analysis of (A) NRF-1 and (B) FKHR mRNA before and after 3 h of moderate exercise with (NA) or without (CON) prior NA administration. Values represent the means $\pm$ s.E.M. (*n*=7).

#### Protein expression in skeletal muscle

PGC1 $\alpha$  protein expression was not affected by NA at rest or after exercise (Fig. 3B). PGC1a protein tended (P=0.09, main effect for time) to increase after exercise with increased protein content observed in four of five subjects. Phosphorylation of p38 MAPK was 3-fold higher (P < 0.05) at rest in NA compared with CON (Fig. 4A). Although exercise did not induce any effects on p38 MAPK phosphorylation in either trial, protein levels remained higher (P < 0.05) in NA. ERK1/2 phosphorylation was lower (P < 0.05) in NA at rest compared with CON (Fig. 4B). ERK1/2 phosphorylation was decreased (P < 0.05) at 180 min, whereas ERK1/2 phosphorylation was unaffected by exercise in NA. JNK phosphorylation was not different between trials at rest and was increased (P < 0.05) after exercise in both trials (Fig. 4C).

# Relationships between PGC1 $\alpha$ mRNA, phosphorylated p38 MAPK and plasma epinephrine

PGC1 $\alpha$  gene expression is regulated by signals that relay metabolic requirements of the cell, such



**Figure 3** (A) Real-time RT-PCR analysis of PGC1 $\alpha$  mRNA and (B) Western blot analysis of PGC1 $\alpha$  protein content measured before and after 3 h of moderate exercise with (NA) or without (CON) prior NA administration. Values represent the means±s.E.M. (*n*=7 for mRNA; *n*=5 for protein). \**P*<0.05, different from corresponding value for CON; †*P*<0.05, different from 0 min of the same trial.

examples including p38 MAPK (Knutti *et al.* 2001) and cAMP (Ichida *et al.* 2002). The increased PGC1 $\alpha$  mRNA content and p38 MAPK phosphorylation correlated significantly at rest ( $r^2=0.84$ , P<0.01), whereas phospho-ERK, phospho-JNK and plasma epinephrine and PGC1 $\alpha$  mRNA were not related.

#### **Cell culture experiments**

To directly examine the effect of p38 MAPK and epinephrine on PGC1 $\alpha$  expression, we incubated human primary myotubes in the presence of A23187, which is a calcium ionophore known to stimulate p38 MAPK phosphorylation (M H S Chan, M J Watt & M A Febbraio, unpublished observations), epinephrine, which is known to elevate cellular cAMP/protein kinase A (PKA) content and NA. Unexpectedly, increasing p38 MAPK phosphorylation (>20-fold) did not affect PGC1 $\alpha$  mRNA content following A23187 treatment (Fig. 5). Incubation with NA also increased

Journal of Molecular Endocrinology (2004) 33, 533-544

**Table 3** Expression of lipid regulatory genes before and after 3 h of exercise with (NA) or without (CON) prior NA ingestion. Values (means  $\pm$  s.E.M.) are expressed as fold change from CON at 0 min (n=7)

	CON		NA	
	Pre	Post	Pre	Post
CPT1	1	2.09±0.67	1.14±0.18	2.82±1.04
FAT/CD36	1	0.75±0.20	0.75±0.17	2.61±0.74*†
HSL	1	$2.11 \pm 1.07$	2.61±1.91	3.18±2.06
PDK4‡	1	$4.33 \pm 1.24$	1.16±0.43	$3.14 \pm 1.09$
UCP3	1	$3.21 \pm 0.70 \ddagger$	$3.56 \pm 0.58^{*}$	2.04±0.29†

\*P<0.05 compared with corresponding time-point for CON; †P<0.05 compared with 0 min of the same trial; ‡P<0.05 compared with 0 min (main effect).

p38 MAPK phosphorylation (17-fold) and did not affect PGC1 $\alpha$ . In contrast, 6 h of epinephrine treatment increased PGC1 $\alpha$  content by 250% (*P*<0.05) and co-incubation with the specific p38 MAPK inhibitor, SB203580, did not prevent this increase.

#### Discussion

Fatty acids are endogenous ligands for the PPARs (Forman et al. 1997) and PPARs stimulate gene expression of proteins central to substrate metabolism. Because plasma FFA and intramuscular long chain fatty acyl CoA increase dramatically during prolonged exercise (Watt et al. 2003), we hypothesized that decreasing plasma FFA availability would suppress the exercise-induced activation of metabolic genes. The main finding from the present study was that, despite complete suppression of plasma FFA with NA, PGC1 $\alpha$ , PPAR $\alpha$  and PPAR $\delta$  mRNA content were increased at rest; however, these effects were not associated with increased mRNA of proteins central to lipid metabolism. The increased PGC1a mRNA coincided with an increase in plasma epinephrine and cell culture studies revealed that epinephrine elevated PGC1a mRNA. Thus, the measured molecular effects of NA were analogous to those induced with exercise and may be related to increased plasma epinephrine.

PPAR $\alpha$  and  $\delta$  increase gene transcription of numerous proteins involved in fatty acid metabolism including CPT1, FAT/CD36, PDK4 and UCP3 (Gulick *et al.* 1994, Wu *et al.* 1999, Huang *et al.* 2002, Muoio *et al.* 2002, Dressel *et al.* 2003).

PPAR $\alpha$  agonists prevent diabetes in OLETF rats (Koh *et al.* 2003) whereas PPAR $\delta$  overexpression increases fatty acid  $\beta$ -oxidation in adipocytes and causes resistance to high fat diet-induced obesity (Wang et al. 2003). In contrast to a previous human study (Tunstall et al. 2002), we report increased PPAR $\alpha$  and, for the first time, increased PPAR $\delta$ mRNA immediately following an acute exercise bout. This is consistent with endurance training studies which have demonstrated increased PPAR $\alpha$ mRNA (Russell et al. 2003) and protein content (Horowitz et al. 2000, Russell et al. 2003). The difference between the present study and that of Tunstall et al. (2002) is likely to be due to the duration (60 vs 180 min) of exercise. Thus, PPAR $\alpha$ and PPAR $\delta$  mRNA are rapidly upregulated following a single prolonged exercise bout and may contribute, at least partially, to the tighter metabolic control and improved fatty acid handling observed after short-term endurance exercise training (Phillips et al. 1996, Spina et al. 1996). Reducing plasma FFA availability via NA ingestion also resulted in a rapid and pronounced increase in **PPARa** and  $\delta$ . The transcriptional response may be a rapid adaptation designed to increase the potential for increased fat oxidative proteins in the event of reduced fatty acid availability. In this regard, rapid transcriptional responses also occur in response to reduced muscle glycogen availability (Pilegaard et al. 2002), suggesting that the availability of metabolic substrates is important for the transcriptional regulation of several transcription factors and metabolic genes.

Despite the rapid changes in PPAR $\alpha/\delta$ , the mRNA responses of the measured downstream target genes were limited. Consistent with previous



Α

**Figure 4** (A) Phospho-p38 MAPK, (B) phospho-ERK1/2 and (C) phospho-JNK protein expression measured before and after 3 h of moderate exercise with (NA) or without (CON) prior NA administration. Values represent the means  $\pm$  s.e.m. (*n*=7). \**P*<0.05, different from corresponding value for CON; †*P*<0.05, different from 0 min of the same trial.

studies (Pilegaard *et al.* 2000, 2002), we report exercise-induced increases in UCP3 and PDK4 mRNA, whereas other proteins involved with fatty acid uptake (FAT/CD36), intramyocellular



**Figure 5** Epineprine increases PGC1a mRNA content. Primary human myotubes were incubated for 6 h with PBS (VEH), NA, a calcium ionophore (Ca) or epinephrine (EPI) in the presence or absence of the specific p38 MAPK inhibitor, SB203580. (A) Cells were lysed and assessed for p38 MAPK phosphorylation by Western blot. The immunoblots (80 µg protein) represent the order of treatments as listed on the Figure below. (B) In another experiment, RNA was extracted after treatment and PGC1a mRNA was assessed by RT-PCR. Values represent the means±s.E.M. (*n*=6). \**P*<0.05, different from VEH, †*P*<0.05, different from +SB203580 within the same treatment.

triacylglycerol hydrolysis (HSL) and mitochondrial fatty acid transport (CPT1) were not altered by exercise, and were generally unaffected by reduced fatty acid availability. These data suggested that changes in the mRNA content of some, but not all, transcription factors and coactivators precede changes in the gene expression of proteins involved in lipid metabolism. Although we observed modest or no increases in the mRNA content of numerous lipid-regulatory genes, we cannot discount the possibility that mRNA changes would occur later in recovery from exercise.

There is currently considerable interest in the role of  $PGC1\alpha$  in numerous cellular functions,

including mitochondrial biogenesis and lipid metabolism, and evidence is emerging linking muscle insulin resistance with mitochondrial dysfunction (Petersen et al. 2003). Both acute (Baar et al. 2002, Terada et al. 2002, Pilegaard et al. 2003, Norrbom et al. 2004) and chronic (Goto et al. 2000, Russell et al. 2003, Short et al. 2003, Terada & Tabata 2004) exercise increase PGC1 $\alpha$  mRNA. In the present study we observed an  $\sim 12$ -fold increase in PGC1 $\alpha$  mRNA immediately following 3 h of cycle exercise in CON and have extended previous studies by demonstrating an  $\sim 70\%$ increase (P=0.09, n=5) of PGC1a protein content immediately after acute exercise. On balance, these findings suggest that acute exercise increases PGC1 $\alpha$  mRNA and protein content, which is presumably a rapid response to metabolic stress designed to co-ordinate changes in skeletal muscle gene expression.

The regulation of PGC1 $\alpha$  is complex and is activated by factors that increase cAMP, and is repressed by estrogen-related receptor (ERR)- $\alpha$ (Ichida et al. 2002), which disassociates from PGC1α when p38 MAPK is activated (Knutti *et al.* 2001). PGC1 $\alpha$  is likely to be regulated by upstream kinases because its protein sequence includes putative phosphorylation targets for PKA, PKC and mitogen-activated protein kinases. NA was unlikely to exert direct effects because the receptor for NA (HM74) is not expressed in skeletal muscle (Tunaru et al. 2003). Instead, the effects are likely to be mediated by secondary changes in the internal metabolic and external hormonal milieu. It is unlikely that the decreased plasma FFA per se affected gene expression, because similar transcriptional responses were observed after exercise when plasma FFA was elevated from rest (0.3-1.4 mM). Plasma epinephrine increased 3-fold with NA at rest (Table 2) and during exercise, and direct examination in skeletal muscle myotubes demonstrated increased PGC1a after epinephrine treatment. Thus, the increased PGC1 $\alpha$  observed in vivo is consistent with the stimulatory cAMP/PKA effects.

Another possible mediator was p38 MAPK, which was phosphorylated to a greater extent in NA compared with CON both prior to and following exercise (Fig. 4A). Activation of p38 MAPK increases PGC1 $\alpha$  transcription (Knutti *et al.* 2001) and removes the inhibitory action of p160 myb resulting in increased stability and half-life of PGC1a (Puigserver et al. 2001, Fan et al. 2004). Despite the close temporal association between p38 MAPK phosphorylation and PGC1a mRNA in vivo, induction of p38 MAPK phosphorylation in vitro did not increase PGC1 $\alpha$  mRNA (Fig. 5). The disparity between our in vitro and in vivo data with regard to PGC1 $\alpha$  mRNA expression with NA treatment suggests that the major function of p38 MAPKs in skeletal muscle is to enhance PGC1a protein stability, rather than acting as a transcriptional regulator. This finding is consistent with previous work in C2C12 myotubes which demonstrated no increase in PGC1a mRNA despite p38 MAPK activation (Fan et al. 2003). A stimulatory role for the other MAPKs on PGC1 $\alpha$  cannot be completely excluded, although ERK1/2 phosphorylation decreased and c-jun N-terminal kinase increased modestly and changes in either of these kinases were not related to the increased PGC1 $\alpha$ . Previous studies have suggested that 5-AMP-activated protein kinase (AMPK) and a Ca<sup>2+</sup>-mediated mechanism (possibly calcineurin) increased PGC1 $\alpha$  expression (Terada *et al.* 2004, Zong et al. 2002). However, AMPK activity was not elevated in human skeletal muscle with NA ingestion at rest (Watt et al. 2004), and it is unlikely that intracellular Ca<sup>2+</sup> increases with NA at rest. Thus, our data suggested that the increased PGC1 $\alpha$ mRNA content observed with NA is most likely due to a secondary effect of increased epinephrine.

It has been postulated that changes in the PGC1α coactivation of PPAR and NRF-dependent transcription may underlie the aberrant fatty acid metabolism in disease states such as type 2 diabetes (Mootha et al. 2003, Patti et al. 2003). In this study, we have observed that the exercise-induced increase in mRNA content of the PPARs, PGC1a and NRF-1 does not occur following NA ingestion, suggesting that the signalling mechanism/s underlying the NA stimulatory effect and exercise are analogous. Although the mechanism(s) of action of NA remains to be elucidated, and no differences in the gene expression of various lipid regulatory proteins were observed after 1.5 h (data not shown), the rapid and pronounced increase in PGC1 $\alpha$  and PPAR $\alpha/\delta$  may promote NA as a potential therapeutic target for improved fatty acid metabolism. Indeed, NA is administered to treat hypertriglyceridemia and lower cholesterol; however, prolonged treatment (>2 weeks) with NA leads to a modest decrease in insulin sensitivity as measured by euglycemic-hyperinsulinemic clamp (Alvarsson & Grill 1996). Thus, the efficacy of NA as a treatment for metabolic disorders is questionable and requires further investigation.

In summary, the results from this study have demonstrated that the mRNA of proteins central to the control of lipid metabolism were generally unaffected following prolonged exercise when FFA availability was attenuated, suggesting that mechanisms other than FFA are important for their gene expression. Despite total suppression of lipolysis, NA ingestion at rest increased the mRNA content of PGC1 $\alpha$  and PPAR $\alpha/\delta$ , which was associated with elevated plasma epinephrine. The magnitude of these changes was analogous to those induced by prolonged exercise. The absence of further increases in the mRNA content of PPAR $\alpha/\delta$  and PGC1 $\alpha$  following exercise in NA suggests that the signaling mechanism(s) underlying the NA stimulatory effect are homologous to those induced by exercise.

#### Acknowledgements

This study was supported by grants from the National Health and Medical Research Council (NHMRC) of Australia (MAF) and a RMIT Faculty of Life Sciences Research Grant (MJW). MJW is a Peter Doherty postdoctoral fellow and MAF is a senior research fellow of the NHMRC.

### References

- Alvarsson M & Grill V 1996 Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders. Scandanavian Journal of Clinical and Laboratory Investigations 56 563–570.
- Baar K, Wende AR, Jones TE, Marison M, Nolte LA, Chen M, Kelly DP & Holloszy JO 2002 Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. *FASEB Journal* 16 1879–1886.
- Baar K, Song Z, Semenkovich CF, Jones TE, Han DH, Nolte LA, Ojuka EO, Chen M & Holloszy JO 2003 Skeletal muscle overexpression of nuclear respiratory factor 1 increases glucose transport capacity. *FASEB Journal* **17** 1666–1673.
- Berthon PM, Howlett RA, Heigenhauser GJ & Spriet LL 1998 Human skeletal muscle carnitine palmitoyltransferase I activity determined in isolated intact mitochondria. *Journal of Applied Physiology* **85** 148–153.
- Bonen A, Dyck DJ, Ibrahimi A & Abumrad NA 1999 Muscle contractile activity increases fatty acid metabolism and transport and FAT/CD36. *American Journal of Physiology* 276 E642–E649.
- Braissant O, Foufelle F, Scotto C, Dauca M & Wahli W 1996 Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. *Endocrinology* **137** 354–366.

- Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J & Greenberg ME 1999 Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell* **96** 857–868.
- Chomczynski P & Sacchi N 1987 Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. *Analytical Biochemistry* **162** 156–159.
- Cortright RN, Zheng D, Jones JP, Fluckey JD, DiCarlo SE, Grujic D, Lowell BB & Dohm GL 1999 Regulation of skeletal muscle UCP-2 and UCP-3 gene expression by exercise and denervation. *American Journal of Physiology* **276** E217–E221.
- Djouadi F, Weinheimer CJ, Saffitz JE, Pitchford C, Bastin J, Gonzalez FJ & Kelly DP 1998 A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice. *Journal of Clinical Investigation* **102** 1083–1091.
- Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P & Muscat GE 2003 The peroxisome proliferator-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. *MolecularEndocrinology* **17** 2477–2493.
- Fan M, Rhee J, St-Pierre J, Handschin C, Puigserver P, Lin J, Jaeger S, Erdjument-Bromage H, Tempst P & Spiegelman B 2003 Suppression of mitochondrial respiration through recruitment of p160 myb binding protein to PGC-1: modulation by p38 MAPK. *Genes and Development* 18 278–289.
- Febbraio MA & Koukoulas I 2000 HSP72 gene expression progressively increases in human skeletal muscle during prolonged, exhaustive exercise. *Journal of Applied Physiology* 89 1055–1060.
- Goto M, Terada S, Kato M, Katoh M, Yokozeki T, Tabata I & Shimokawa T 2000 cDNA cloning and mRNA analysis of PGC-1 in epitrochlearis muscle in swimming-exercised rats. *Biochemical and Biophysical Research Communications* 274 350–354.
- Gulick T, Cresci S, Caira T, Moore DD & Kelly DP 1994 The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. *PNAS* **91** 11012–11016.
- Hood DA 2001 Invited review: Contractile activity-induced mitochondrial biogenesis in skeletal muscle. *Journal of Applied Physiology* **90** 1137–1157.
- Horowitz JF, Leone TC, Feng W, Kelly DP & Klein S 2000 Effect of endurance training on lipid metabolism in women: a potential role for PPARalpha in the metabolic response to training. *American Journal of Physiology. Endocrinology and Metabolism* 279 E348–E355.
- Huang B, Wu P, Bowker-Kinley MM & Harris RA 2002 Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin. *Diabetes* **51** 276–283.
- Ichida M, Nemoto S & Finkel T 2002 Identification of a specific molecular repressor of the peroxisome proliferator-activated receptor γ coactivator a (PGC-1 a). *Journal of Biological Chemistry* 277 50991–50995.
- Kelley DE, Goodpaster BH & Storlien L 2002 Muscle triglyceride and insulin resistance. *Annual Review of Nutrition* **22** 325–346.
- Kliewer SA, Xu HE, Lambert MH & Willson TM 2001 Peroxisome proliferator-activated receptors: from genes to physiology. *Recent Progress in Hormone Research* 56 239–263.
- Knutti D, Kressler D & Kralli A 2001 Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a repressor. *PNAS* **98** 9713–9718.
- Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS, Youn JH & Lee KU 2003 Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. *Diabetes* 52 2331–2337.

Larrouy D, Vidal H, Andreelli F, Laville M & Langin D 1999 Cloning and mRNA tissue distribution of human PPARgamma coactivator-1. *International Journal of Obesity and Related Metabolic Disorders* 23 1327–1332.

Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D & Groop LC 2003 PGC-1α responsive genes involved in oxidative phosphorylation are co-ordinately downregulated in human diabetes. *Nature Genetics* **34** 267–273.

Muoio DM, Way JM, Tanner CJ, Winegar DA, Kliewer SA, Houmard JA, Kraus WE & Dohm GL 2002 Peroxisome proliferator-activated receptor-alpha regulates fatty acid utilization in primary human skeletal muscle cells. *Diabetes* 51 901–909.

Norrbom J, Sundberg CJ, Ameln H, Kraus WE, Jansson E & Gustafsson T 2004 PGC-1α mRNA expression is influenced by metabolic perturbation in exercising human skeletal muscle. *Journal of Applied Physiology* **96** 189–194.

Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, Kahn CR & Mandarino LJ 2003 Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC-1 and NRF-1. *PNAS* **100** 8466–8471.

Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW & Shulman GI 2003 Mitochondrial dysfunction in the elderly: possible role in insulin resistance. *Science* **300** 1140–1142.

Phillips SM, Green HJ, Tarnopolsky MA, Heigenhauser GF, Hill RE & Grant SM 1996 Effects of training duration on substrate turnover and oxidation during exercise. *Journal of Applied Physiology* 81 2182–2191.

Pilegaard H, Ordway GA, Saltin B & Neufer PD 2000 Transcriptional regulation of gene expression in human skeletal muscle during recovery from exercise. *American Journal of Physiology. Endocrinology and Metabolism* **279** E806–E814.

Pilegaard H, Keller C, Steensberg A, Helge JW, Pedersen BK, Saltin B & Neufer PD 2002 Influence of pre-exercise muscle glycogen content on exercise-induced transcriptional regulation of metabolic genes. *Journal of Physiology* **541** 261–271.

Pilegaard H, Saltin B & Neufer PD 2003 Exercise induces transient transcriptional activation of the PGC-1α gene in human skeletal muscle. *Journal of Physiology* **546** 851–858.

Puigserver P & Spiegelman BM 2003 Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α): transcriptional coactivator and metabolic regulator. *Endocrine Reviews* **24** 78–90.

Puigserver P, Wu Z, Park CW, Graves R, Wright M & Spiegelman BM 1998 A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. *Cell* **92** 829–839.

Puigserver P, Rhee J, Lin J, Wu Z, Yoon JC, Zhang CY, Krauss S, Mootha VK, Lowell BB & Spiegelman BM 2001 Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPARgamma coactivator-1. *Molecular Cell* **8** 971–982.

Russell AP, Feilchenfeldt J, Schreiber S, Praz M, Crettenand A, Gobelet C, Meier CA, Bell DR, Kralli A, Giacobino JP & Deriaz O 2003 Endurance training in humans leads to fiber type-specific increases in levels of peroxisome proliferator-activated receptor-gamma coactivator-1 and peroxisome proliferator-activated receptor-alpha in skeletal muscle. *Diabetes* **52** 2874–2881.

- Short KR, Vittone JL, Bigelow ML, Proctor DN, Rizza RA, Coenen-Schimke JM & Nair KS 2003 Impact of aerobic exercise training on age-related changes in insulin sensitivity and muscle oxidative capacity. *Diabetes* 52 1888–1896.
- Spina RJ, Chi MM, Hopkins MG, Nemeth PM, Lowry OH & Holloszy JO 1996 Mitochondrial enzymes increase in muscle in response to 7–10 days of cycle exercise. *Journal of Applied Physiology* 80 2250–2254.

Terada S &Tabata I 2004 Effects of acute bouts of running and swimming exercise on PGC-1α protein expression in rat epitrochlearis and soleus muscle. *American Journal of Physiology*. *Endocrinology and Metabolism* **286** E208–E216.

Terada S, Goto M, Kato M, Kawanaka K, Shimokawa T &Tabata I 2002 Effects of low-intensity prolonged exercise on PGC-1 mRNA expression in rat epitrochlearis muscle. *Biochemical and Biophysical Research Communications* **296** 350–354.

Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K & Offermanns S 2003 PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. *Nature Medicine* 9 352-355.

Tunstall RJ, Mehan KA, Wadley GD, Collier GR, Bonen A, Hargreaves M & Cameron-Smith D 2002 Exercise training increases lipid metabolism gene expression in human skeletal muscle. *American Journal of Physiology. Endocrinology and Metabolism* 283 E66–E72.

Vega RB, Huss JM & Kelly DP 2000 The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. *Molecular and Cellular Biology* 20 1868–1876.

van der Vusse GJ & Reneman RS 1996 Lipid metabolism in muscle. In Handbook of Physiology: Exercise: Regulation and Integration of Multiple Systems, pp 952–994. Eds LB Rowell & JT Shephard. New York: Oxford Press.

Wang YX, Lee CH, Tiep S, Yu RT, Ham J, Kang H & Evans RM 2003 Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. *Cell* **113** 159–170.

Watt MJ, Heigenhauser GJF, O'Neill M & Spriet LL 2003 Hormone sensitive lipase activity and fatty acyl CoA content in human skeletal muscle during prolonged exercise. *Journal of Applied Physiology* **95** 314–321.

Watt MJ, Holmes AG Steinberg GR, Mesa JL, Kemp BE & Febbraio MA 2004 Reduced plasma FFA availability increases net triacylglycerol degradation, but not GPAT or HSL activity, in human skeletal muscle. *American Journal of Physiology Endocrinology* and Metabolism 287 E120–127.

Wu P, Inskeep K, Bowker-Kinley MM, Popov KM & Harris RA 1999 Mechanism responsible for inactivation of skeletal muscle pyruvate dehydrogenase complex in starvation and diabetes. *Diabetes* 48 1593–1599.

Zong H, Ren JM, Young LH, Pypaert M, Mu J, Birnbaum MJ & Shulman GI 2002 AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. *PNAS* **99** 15983–15987.

Received in final form 18 June 2004 Accepted 12 July 2004